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Abstract
Background: Chronic cerebrospinal venous insufficiency (CCSVI) was described as a vascular condition characterized by
anomalies of veins outside the skull was reported to be associated with multiple sclerosis (MS). The objective was to assess
the associations between HLA DRB1*1501 status and the occurrence of CCSVI in MS patients.
Methodology/Principal Findings: This study included 423 of 499 subjects enrolled in the Combined Transcranial and
Extracranial Venous Doppler Evaluation (CTEVD) study. The HLA DRB1*1501 status was obtained in 268 MS patients and 155
controls by genotyping rs3135005, a SNP associated with DRB1*1501 status. All subjects underwent a clinical examination
and Doppler scan of the head and neck. The frequency of CCSVI was higher (OR=4.52, p,0.001) in the MS group 56.0% vs.
21.9% in the controls group and also higher in the progressive MS group 69.8% vs. 49.5% in the non-progressive MS group.
The 51.9% frequency of HLA DRB1*1501 positivity (HLA
+) in MS was higher compared (OR=2.33, p,0.001) to 31.6% to
controls. The HLA
+ frequency in the non-progressive (51.6%) and progressive MS groups (52.3%) was similar. The frequency
of HLA
+ CCSVI
+ was 40.7% in progressive MS, 27.5% in non-progressive MS and 8.4% in controls. The presence of CCSVI was
independent of HLA DRB1*1501 status in MS patients.
Conclusions/Significance: The lack of strong associations of CCSVI with HLA DRB1*1501 suggests that the role of the
underlying associations of CCSVI in MS should be interpreted with caution. Further longitudinal studies should determine
whether interactions between these factors can contribute to disease progression in MS.
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Introduction
Recently reported strong associations between MS and a
condition defined as chronic cerebrospinal venous insufficiency
(CCSVI), have challenged the prevailing view that central nervous
system damage (CNS) in multiple sclerosis (MS) is predominantly
the result of abnormal immune responses against the patient’s
nervous tissue [1,2,3].
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16802CCSVI has been described as a vascular condition characterized
by anomalies of the main extra-cranial cerebrospinal (CS) venous
routes that interfere with normal CS venous outflow. These
anomalies have been reported to affect the internal jugular veins
(IJV), the vertebral veins (VV) and the azygous vein (AZY), and can
be detected using venous echo-color Doppler (ECD) and catheter
venography [1,2,3]. It has been hypothesized that CS venous
anomalies may cause alterations to blood flow that eventually result
in iron deposition, degeneration of neurons and characteristic brain
injury patterns found in MS [4,5]. Nevertheless, some studies have
questioned the existence of the CCSVI in patients with MS [6,7].
CCSVI is a controversial area in MS research and it is
important to critically assess the role of CCSVI and its
pathophysiological mechanisms so that the implications, if any,
for the treatment and prevention of MS can be determined.
However, the mechanisms that cause the reported associations
between CCSVI and MS are not known. A valuable scientific step
in this direction would be to place CCSVI in the context of other
known associations in MS.
The genetics of MS has been systematically investigated in
genomewide association studies (GWAS) [8,9]. These studies have
confirmed key associations with the MHC locus and identified
additional genetic variations associated with the risk of developing
MS [10]. Genetic epidemiology studies have also demonstrated
that the genetics of MS is complex and involves interplay between
genes and environmental factors. However, the genetic variations
and the environmental factors do not individually explain the
majority of the variance in the risk of developing MS [10,11,12].
There is suggestive evidence that genetic risk factors such as HLA
DRB1*1501 and environmental risk factors such as Epstein-Barr
virus (EBV) exposure and cigarette smoking are also associated
with disease progression. Except for Ferlini et al. [13] who
conducted preliminary analysis of copy number variations
associated CCSVI in a group of 15 MS patients, no information
is available on the role of genetic factors in CCSVI MS.
The goal of this study was to assess the associations of CCSVI
with HLA DRB1*1501, a genetic variation that has been
consistently linked to MS in familial and association studies.
Methods
Study Population
Study Design. This project utilized samples from the
Combined Transcranial and Extracranial Venous ECD
Evaluation (CTEVD study), which was designed to assess the
prevalence of CCSVI in a large cohort of patients with MS,
clinically isolated syndrome (CIS), healthy controls (HC) and
controls with other neurological diseases (OND) using specific
echo-color Doppler (ECD) criteria (see Supplementary Material in
[14]). The CTEVD study enrolled a total of 499 subjects,
including 289 MS, 21 CIS, 163 HC and 26 OND.
The participants received a clinical examination (not blinded)
and an ECD scan of the head and neck (performed by a technician
blinded to the subjects’ diagnosis) [14]. Subjects also provided
blood samples for genetic analysis that were also evaluated by a
technician who was blinded to the subjects’ disease or CCSVI
status.
The study was approved by the University at Buffalo Human
Subjects Institutional Review Board and all participants provided
written informed consent.
Echo-color Doppler Data Analysis
Cerebral venous return was examined by using the echo-color
Doppler (ECD Esaote-Biosound My Lab 25) equipped with 2.5
and 7.5–10 Mhz transducers (Genoa, Italy), with the subject
positioned on a tilt bed at 90u and 0u [2,3].
The specific details of the length of exam, contraindications and
limitations, subject assessment, examination guidelines, annotation
documentation, specific Doppler parameters, criteria definitions,
description of probes, positioning of the subject, techniques used,
fulfilment of VH criteria and pathology definitions are provided
elsewhere [14].
The presence of CCSVI was defined as the presence of two or
more venous hemodynamic (VH) criteria as described in [14]. A
subject was considered CCSVI-positive if $2 VH criteria were
fulfilled. A subject was considered CCSVI-negative if ,2V H
criteria were fulfilled. Subjects who were not assessed for some VH
criterion, due to technical difficulty, were assumed not to have
fulfilled that criterion. Subjects who fulfilled exactly one of the
other 4 criteria and were not assessed on one VH criterion were
classified CCSVI borderline; these individuals were conservatively
categorized as CCSVI negative in the statistical analyses
potentially biasing associations toward the null.
Genotyping
HLA DRB1*1501 status was obtained by genotyping DNA from
peripheral blood for rs3135005, a SNP strongly correlated with
HLA DRB1*1501 status, using an allele discrimination kit (Assays-
on-Demand genotyping kit, Applied Biosystems, Redwood City,
CA). Genotyping was performed on a MX4000 (Stratagene) real-
time thermal cycler and analyzed using the MX4000 software.
Non-template controls produced negligible background signals.
We also amplified DNA fragments for 9 DNA samples (3 each
of C/C, C/T and C/T genotypes) previously genotyped by allele
discrimination (forward primer: 59 TGC CTT TTA AAA TCC
AAA GAC AT; reverse primer: 59 AGA GCG AGA CCA GGA
ACA AA) spanning the rs3135005 C/T SNP [15]. PCR products
were digested with Afl 11 restriction enzyme and then analyzed on
an agarose gel. The agreement between the RFLP results and
allele discrimination was 100% on the nine samples examined.
Data Analysis
SPSS (SPSS Inc., Chicago, IL, version 15.0) statistical program
was used for all statistical analyses.
Subjects with relapsing-remitting (RR) MS were categorized as
non-progressive MS whereas those with relapsing and non-
relapsing forms of secondary progressive (SP) and primary-
progressive (PP) MS were categorized as progressive MS [16].
The homozygous rs3135005 and heterozygous genotypes were
categorized as DRB1*1501 positive whereas the homozygous wild
type allele was categorized as DRB1*1501 negative.
One-way ANOVA followed bypost-hoc independent sample t-tests
were used to test for differences in means of continuous demographic
variables such as age, age of onset, and disease duration. The chi-
square test was used for analysis of count variables for categorical data
and the Fisher exact test was used where appropriate.
Multinomial logistic regression with the Control-Non-progres-
sive MS-Progressive MS status as the nominal dependent variable
categories, age as a covariate and gender as a factor was also used
to assess the role of CCSVI or HLA DRB1*1501. Analyses were
conducted with main effects models containing either CCSVI or
HLA DRB1*1501 and both CCSVI and HLA DR*1501.I n
addition, models containing an additional CCSVI *HLA
DRB1*1501 interaction term were also assessed when significant
main effects were observed for both CCSVI and HLA DRB1*1501.
To correct for multiple comparisons, a conservative Type I
error level of 0.01 was used to assess significance; a trend was
assumed if the Type I error level #0.10.
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Demographic and Clinical Characteristics
The CONSORT diagram for the study is summarized in
Figure 1. Genotyping was available for 472 subjects. To avoid the
effects of small samples and confusion stemming from three more
groups, subjects with other neurological diseases (OND, n=24),
clinically isolated syndrome (CIS, n=20) and neuromyelitis optica
(NMO, n=5) were excluded, yielding 423 subjects: 155 healthy
controls and 268 CDMS in the statistical analysis. The
comparisons were limited to healthy controls and patients with
clinically definite MS according to the McDonald criteria [17].
Of the 268 MS patients, 182 had RRMS and 86 had
progressive forms of MS. The clinical and demographic features
of controls and MS patients are summarized in Table 1. There
was a significant difference in the male to female ratio between MS
cases and controls groups due to enrollment of spousal controls;
analyses were adjusted for gender where appropriate.
Frequency of CCSVI and HLA DRB1*1501 and CCSVI
The frequencies of CCSVI and HLA DRB1*1501 positive
subjects are summarized in Table 2.
The frequency for the homozygous HLA DRB1*1501 positive,
heterozygous and homozygous HLA DRB1*1501 negative geno-
types in MS patients were 18.7%, 33.2%, and 48.1%, respectively;
the corresponding frequencies of these genotypes in controls were
5.8%, 25.8%, and 68.4%, respectively (chi-square=20.6,
p,0.001). The observed allele frequency for the disease-associated
HLA DRB1*1501 allele in MS patients and controls were 35.3%
and 18.7%, respectively. The odds ratio for the association
between HLA DRB1*1501 positivity and the MS diagnosis was 2.33 (chi-square=16.3, p,0.001). In multinomial logistic regres-
sion correcting for age and gender, there was no evidence for a
significant association of HLA DRB1*1501 status (52.3% in
progressive MS vs. 51.3% in non-progressive MS, p=0.78) with
non-progressive MS/progressive MS status.
The odds ratio for the association between CCSVI status and
the MS diagnosis was 4.52 (chi-square=46.2, p,0.001). In
multinomial logistic regression correcting for age and gender,
there was a significant association for CCSVI positivity (69.8% in
progressive MS vs. 49.5% in non-progressive MS, p=0.003) with
non-progressive MS/progressive MS status.
We additionally conducted multinomial logistic regression
correcting for age and gender with both CCSVI status and HLA
DRB1*1501 status present among the predictor variables. CCSVI
status was significantly associated with the Controls vs. Progressive
MS (p,0.001) and Non-progressive vs. Progressive MS (p=0.003)
comparisons. There was trend toward an association between HLA
DRB1*1501 status in the Controls vs. Progressive MS (p=0.062)
Figure 1. CONSORT flow chart for the study.
doi:10.1371/journal.pone.0016802.g001
Table 1. Demographic and clinical characteristics of the
cohort.
Demographics MS Controls p-value
Females: Males (% Female) 201: 67 (75%) 83*: 72 (54%) ,0.001
{
Disease course:
Relapsing-remitting
Secondary progressive
Relapsing SP
Primary progressive or
primary relapsing
182 (67.9%)
182 (67.9%)
18 (6.7%)
11 (4.1%)
Race/Ethnicity:
Caucasian-American
African-American
Hispanic/Latino
Asian
Other/Unknown/Not given
243 (93.1%)
13 (5.0%)
4( 1 . 5 % )
0 (0%)
1( 0 . 4 % )
136 (89.5%)
136 (89.5%)
1 (0.7%)
4 (2.6%)
0 (0%)
0.20
#
Age, years 46.4612.1 44.8614.1 0.24
"
Disease duration*, years 14.8610.7 –
Median EDSS* (IQR) 2.5 (4.0)
The continuous variables are expressed as mean 6 SD and the categorical
variables as frequency (%).
*1 subject self-reported as transgender male, counted as a male.
#Fisher exact test for frequency of Whites to Non-whites in MS vs. Controls. For
frequency of Black/African Americans to non-Black/African-Americans in MS
vs. Controls p=1.
{Fisher exact test.
"t-test.
doi:10.1371/journal.pone.0016802.t001
Table 2. The distribution of the HLA DRB1*1501 and CCSVI in
MS and controls.
Demographics DRB1*1501 Positive CCSVI Positive
Controls 49/155 (31.6%) 34/155 (21.9%)
All MS 139/268 (51.9%) 150/268 (56.0%)
Non-progressive MS 94/182 (51.6%) 90/182 (49.5%)
Progressive MS 45/86 (52.3%) 60/86 (69.8%)
Odds ratios for DRB1*1501: For MS vs. Controls=2.33 (95% CI: 1.54–3.53,
p,0.001). For Non-progressive vs. Progressive MS=1.03 (0.62–1.72, p=1.0).
Odds ratios for CCSVI status: For MS vs. Controls=4.52 (95% CI: 2.88–7.10,
p,0.001). For Non-progressive vs. Progressive MS=2.36 (1.37–4.07, p=0.002).
doi:10.1371/journal.pone.0016802.t002
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in the Non-progressive vs. Progressive MS (p=0.84) comparison.
The associations between HLA DRB1*1501 status and CCSVI
status were significant when the entire study population was
considered (chi-square=10.3, Fisher exact test p=0.002). How-
ever, there was no evidence for associations within the Control
(chi-square=0.88, Fisher exact test p=0.41) sub-group and only a
trend in the MS (chi-square=3.15, Fisher exact test p=0.085)
sub-group. This suggests that the significant associations in the
entire study population are largely the result of the indirect
association or confounding of the HLA DRB1*1501 status and MS,
which exhibits more CCSVI.
Table 3 summarizes the dependence of the Control/MS status
and non-progressive MS/progressive MS status variables for
different combinations of the HLA DRB1*1501 status and CCSVI
status variables. The frequency of CCSVI negative- HLA
DRB1*1501 negative status in Controls was more than two-fold
greater than in MS patients (54.8% in Controls vs. 23.9% in MS),
whereas the frequency of CCSVI positive- HLA DRB1*1501
positive status in MS patients (8.4% in Controls vs. 31.7% in MS)
was more than three-fold greater than in Controls. The frequency
of CCSVI positive- HLA DRB1*1501 positive status in the
progressive MS sub-group was nearly four-fold greater than in
Controls (8.4% in Controls vs. 40.7% in Progressive MS).
Multinomial logistic regression with models containing both main
effects and an interaction term between HLA DRB1*1501 status
and CCSVI status variables did not provide evidence for a role for
interactions.
Discussion
The goal of this study was to assess the associations of CCSVI
with HLA DR*1501, a genetic variation that has been consistently
linked to MS in familial and association studies. We found that the
frequency of CCSVI positivity and HLA DRB1*1501 positivity
were both increased in MS compared to controls. However, the
frequency of CCSVI positivity was also increased in progressive
forms of MS compared to the non-progressive forms of MS.
We reasoned that because HLA DRB1*1501 was well estab-
lished as a genetic factor associated with the risk of developing MS,
it would provide a reference relative to which the role of CCSVI
could be evaluated. The goals were therefore to critically assess the
associations of CCSVI with MS and MS progression vis-a `-vis HLA
DRB1*1501. We did not obtain evidence to support a role for
statistical interactions between HLA DRB1*1501 and CCSVI
status, which suggests that there is no synergistic association
between HLA DRB1*1501 and CCSVI with MS. This is evidenced
in non-progressive forms of MS because the relative proportions
were the similar across the HLA DRB1*1501 negative-CCSVI
negative, HLA DRB1*1501 positive -CCSVI negative, HLA
DRB1*1501 negative-CCSVI positive, and HLA DRB1*1501
positive-CCSVI positive combinations. There was a higher
relative frequency of the HLA DRB1*1501 positive-CCSVI
positive combination compared to the HLA DRB1*1501 nega-
tive-CCSVI negative combination in progressive MS but this was
not significant. The greater relative frequency of the HLA
DRB1*1501 negative-CCSVI negative combination compared to
the HLA DRB1*1501 positive-CCSVI positive combination in the
control group could be interpreted as indicating that the absence
of CCSVI is protective.
Although the association between susceptibility to MS and
HLA-DRB1*1501 is well established, its relationship to disease
characteristics and/or disease progression is controversial. Several
studies have linked the DR2 haplotype to disease progression [18]
especially if extreme cases (benign vs. malignant) are compared
[19] but there is also evidence that a negative status for
DRB1*1501 may be associated with a worse prognosis [20]. Our
results however, did not provide support for a protective role for
DRB1*1501 negative status in progressive MS status.
Interestingly, despite the lower prevalence of CCSVI in our
sample compared to the results previously reported [2], the odds
ratio for the association of CCSVI with MS was 4.52 compared to
the odds ratio of 2.33 for the association of HLA DRB1*1501 with
MS. Additionally, CCSVI positivity appeared associated with
progressive forms of MS but we did not obtain evidence that HLA
DRB1*1501 positivity was associated with progressive forms of MS
in our sample. The exact reasons for the associations between
CCSVI and progressive forms of MS are not known: only
prospective longitudinal studies can address whether the associa-
tions are the result of CCSVI modifying disease progression or
alternatively, because CCSVI is secondary to the underlying
inflammatory/degenerative disease processes.
A potential criticism of our methodology is the use of ECD,
which is sometimes viewed as technically demanding and strongly
operator dependent. We used a single machine for all subjects
and the one operator received extensive training in assessing
CCSVI in MS; the operator’s intra-rater reproducibility was
Kappa 0.75 agreement with 89.3% in a scan-rescan test [14].
The operator was blinded to the subjects’ clinical diagnosis and
we included patients with OND because the obvious presence of
disabilities in some patients adversely impacts the effectiveness of
blinding [14]. Catheter venography and magnetic resonance
venography are alternative imaging modalities capable of
providing greater anatomical detail than ECD. However, these
techniques are difficult to apply for the large sample sizes
required for genetic analyses, e.g., the CV is an invasive exam
and value of MRV for diagnosis of CCSVI is limited [21,22,23].
ECD provides qualitatively different functional assessments of
flow velocity changes in response to postural adjustments that are
complementary to, but not possible with the other imaging
methods.
Table 3. The joint distribution of the HLA DRB1*1501 status and CCSVI status.
DRB1*1501 Negative DRB1*1501 Positive
Demographics CCSVI Negative CCSVI Positive CCSVI Negative CCSVI Positive
Controls 85 (54.8%) 21 (13.5%) 36 (23.2%) 13 (8.4%)
All MS 64 (23.9%) 65 (24.3%) 54 (20.1%) 85 (31.7%)
Non-progressive MS 48 (26.4%) 40 (22.0%) 44 (24.2%) 50 (27.5%)
Progressive MS 16 (18.6%) 25 (29.1%) 10 (11.6%) 35 (40.7%)
doi:10.1371/journal.pone.0016802.t003
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preliminary analysis of copy number variations associated with
CCSVI in a group of 15 MS patients, no information is available
on the role of genetic factors in CCSVI. These authors reported
that CCSVI was associated of copy number variations in the HLA
region for a small group of 15 MS patients [13]. In other diseases
with venous pathophysiologies, a role for gender, and environ-
mental and genetic factors is suggested. Female gender, older age,
and pregnancy are risk factors for chronic venous diseases [24] and
women have greater frequency of variant hepatic veins [25].
Women have also been reported to have a smaller internal jugular
vein size than men (1.48 for men vs. 1.27 in women) [26]. Venous
malformations may have genetic contributions and a ‘‘double-hit’’
mechanism has been invoked to explain incomplete penetrance
and variability [27,28]. The R849W substitution in the angio-
poietin receptor Tie2 [29], an endothelial receptor tyrosine kinase,
has been linked to familial venous malformations and results in
variable thickness or lack of smooth-muscle cells in the veins of
patient lesions. Interestingly Tie2 activates Stat1, which is also
critical in interferon signaling. We did not observe, age, gender or
disease duration differences in the occurrence of CCSVI (results
not shown) in MS. However, a more detailed analysis of candidate
gender-dimorphic factors, e.g., vein diameters and autoimmune
factors, is warranted as these could strongly interact with changes
in cerebral venous outflow.
HLA DRB1*1501 has been consistently linked to MS suscepti-
bility in genetic studies. We did not find evidence for associations
between CCSVI diagnosis and HLA DRB1*1501 status for MS
patients.
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